KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $94.0 million.

  • Sarepta Therapeutics' Accounts Payables fell 2084.55% to $94.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.0 million, marking a year-over-year decrease of 2084.55%. This contributed to the annual value of $214.4 million for FY2024, which is 3002.95% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Accounts Payables stood at $94.0 million for Q3 2025, which was down 2084.55% from $136.7 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Accounts Payables high stood at $214.4 million for Q4 2024, and its period low was $44.2 million during Q3 2021.
  • Over the past 5 years, Sarepta Therapeutics' median Accounts Payables value was $95.9 million (recorded in 2022), while the average stood at $104.6 million.
  • Over the last 5 years, Sarepta Therapeutics' Accounts Payables had its largest YoY gain of 18821.58% in 2021, and its largest YoY loss of 4074.31% in 2021.
  • Over the past 5 years, Sarepta Therapeutics' Accounts Payables (Quarter) stood at $76.7 million in 2021, then rose by 24.93% to $95.9 million in 2022, then skyrocketed by 72.01% to $164.9 million in 2023, then surged by 30.03% to $214.4 million in 2024, then plummeted by 56.16% to $94.0 million in 2025.
  • Its Accounts Payables was $94.0 million in Q3 2025, compared to $136.7 million in Q2 2025 and $156.1 million in Q1 2025.